SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-029317
Filing Date
2023-02-09
Accepted
2023-02-09 09:01:31
Documents
12
Period of Report
2023-02-09
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d379700d8k.htm   iXBRL 8-K 34543
  Complete submission text file 0001193125-23-029317.txt   155309

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA fstx-20230209.xsd EX-101.SCH 2846
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE fstx-20230209_lab.xml EX-101.LAB 17166
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fstx-20230209_pre.xml EX-101.PRE 10785
6 EXTRACTED XBRL INSTANCE DOCUMENT d379700d8k_htm.xml XML 3223
Mailing Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT
Business Address 35 PARKWOOD DRIVE BABRAHAM RESEARCH CAMPUS CAMBRIDGE X0 CB22 3AT 44 1223 497400
F-star Therapeutics, Inc. (Filer) CIK: 0001566373 (see all company filings)

IRS No.: 522386345 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37718 | Film No.: 23601468
SIC: 2834 Pharmaceutical Preparations